Plasma-based proteomics analysis of molecular pathways in canine diabetes mellitus after astaxanthin supplementation
4
Issued Date
2025-05-01
Resource Type
eISSN
19326203
Scopus ID
2-s2.0-105004429795
Journal Title
PLoS ONE
Volume
20
Issue
5 April
Rights Holder(s)
SCOPUS
Bibliographic Citation
PLoS ONE Vol.20 No.5 April (2025)
Suggested Citation
Phochantachinda S., Photcharatinnakorn P., Chatchaisak D., Sakcamduang W., Chansawhang A., Buranasinsup S., Suemanotham N., Chantong B. Plasma-based proteomics analysis of molecular pathways in canine diabetes mellitus after astaxanthin supplementation. PLoS ONE Vol.20 No.5 April (2025). doi:10.1371/journal.pone.0321509 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/110135
Title
Plasma-based proteomics analysis of molecular pathways in canine diabetes mellitus after astaxanthin supplementation
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
The hyperglycemic state in diabetes mellitus induces oxidative stress and inflammation, contributing to diabetic tissue damage and associated complications. Astaxanthin, a potent antioxidant carotenoid, has been investigated for its potential to prevent and manage diabetes across various species; however, its effect on client-owned dogs remains poorly studied. This study explored the impact of astaxanthin supplementation on canine diabetes mellitus using a proteomics approach. A total of 18 client-owned dogs were enrolled: 6 dogs with diabetes mellitus and 12 clinically healthy dogs. The diabetic dogs received their standard treatment regimen along with daily oral supplementation of 12mg of astaxanthin (1.5–2.4mg/kg) for 90 days. Plasma samples were collected at the beginning and end of the study period for proteomics analysis. After astaxanthin supplementation, significant alterations in the expression of proteins associated with the complement system, coagulation cascade, JAK–STAT signaling, and protein kinase C signaling (all of which contribute to inflammation and oxidative stress) were observed. Astaxanthin exhibited potential for reducing diabetes-associated complications, such as insulin resistance, vascular dysfunction, nephropathy, and cardiac issues, even though it did not affect clinical parameters (hematology, plasma biochemistry, blood glucose, and serum fructosamine). These findings suggest that astaxanthin may be a valuable complementary therapy for managing diabetes-related complications in canines.